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A Double-Blind Randomized Placebo-Controlled Trial of
Oral Naltrexone for Heavy-Drinking Smokers Seeking
Smoking Cessation Treatment
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Lorenzo Leggio , Susan E. Ramsey, Richard A. Brown, and Stephanie S. O’Malley
Background: Post hoc analyses of 2 randomized controlled trials suggest naltrexone may reduce
alcohol use and improve smoking cessation outcomes among heavy drinkers receiving smoking cessa-
tion treatment. However, no studies have been conducted specifically to examine naltrexone for this
purpose or to test whether naltrexone has benefit when added to smoking cessation counseling that
explicitly addresses heavy drinking.
Methods: We recruited heavy-drinking smokers from the community and randomized them to
receive 10 weeks of either (i) 50 mg naltrexone (n = 75) or (ii) placebo (n = 75) daily. Participants
received 6 weeks of transdermal nicotine patch and 6 sessions of counseling that addressed both heavy
drinking and smoking. Participants were followed for 26 weeks after their target quit smoking date.
Results: Across medication conditions, there were substantial reductions at follow-up in percent
heavy drinking days (primary outcome) and average drinks per week (secondary outcome). However,
participants receiving naltrexone did not differ significantly from those receiving placebo on percent
heavy drinking days (effect size d = 0.04, 95% CI [0.30, 0.22], p = 0.76) or average drinks per week
(d = 0.09, 95% CI [0.35, 0.18], p = 0.54) during follow-up. Naltrexone compared to placebo was
not associated with a significant increase in smoking abstinence rates during follow-up, odds
ratio = 0.93, 95% CI [0.46, 1.86], p = 0.83. The effect of naltrexone on these outcomes was not signifi-
cantly moderated by current alcohol dependence or gender.
Conclusions: Results indicate that heavy-drinking smokers, including those with current alcohol
dependence, can make substantial reductions in drinking in the context of smoking cessation treatment.
However, this study provided no evidence that naltrexone is efficacious for enhancing reductions in
drinking or improving smoking cessation in this population. Limitations of this study included lower-
than-desired sample size and modest adherence to study medication.
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GREATER ALCOHOL USE is positively associatedwith smoking initiation and escalation to regular cigar-
ette use and dependence (Kahler et al., 2009). Smokers are
more than twice as likely as nonsmokers to be hazardous
drinkers (McKee et al., 2007), and combined heavy alcohol
use and smoking inflict significant harmful health effects
(Ebbert et al., 2005; Meyerhoff et al., 2006; Schroder et al.,
2002). Alcohol use is among the most common smoking
relapse precipitants (Baer and Lichtenstein, 1988; Borland,
1990; Shiffman et al., 1996). Heavy drinkers report that over
40% of their first smoking lapses during a quit attempt
occurred when they were drinking alcohol (Kahler et al.,
2010). In observational (Augustson et al., 2008; Dollar et al.,
2009; Kahler et al., 2009) and clinical studies (Cook et al.,
2012; Humfleet et al., 1999; Smith et al., 1999; Toll et al.,
2012), greater alcohol use has been associated with a reduced
odds of smoking cessation with episodic heavy drinking (4+
drinks/d in women; 5+ drinks/d in men) being the most
robust predictor of poor smoking outcomes (Cook et al.,
2012; Kahler et al., 2009; Leeman et al., 2008; Murray et al.,
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1995). Therefore, addressing heavy alcohol use in smokers
who are making a quit smoking attempt is a pressing public
health priority.
In the first trial of its kind, Kahler and colleagues (2008)
tested the efficacy of a smoking cessation treatment targeted
to non-alcohol-dependent heavy drinkers that incorporated a
brief intervention to motivate reductions in alcohol consump-
tion. Results showed promise for this approach in reducing
alcohol consumption over 6 months, but positive effects on
smoking cessation tended to fade over time. This lack of sus-
tained effect on smoking cessation was primarily due to a
lack of impact among the heaviest drinkers in the sample. In
a subsequent study, Toll and colleagues (2015) incorporated
brief intervention to reduce alcohol use in heavy drinkers
calling a state smoking quitline. Alcohol-focused counseling
for smoking cessation was significantly more effective in pro-
moting smoking cessation at 7 months postcounseling com-
pared to standard quitline counseling. A trend toward
reduced prevalence of heavy drinking in the alcohol-focused
versus standard counseling was also observed. These studies
highlight the potential value of combined interventions that
simultaneously address smoking and alcohol use among
heavy drinkers seeking smoking cessation treatment.
An intriguing possibility for enhancing alcohol use reduc-
tions and smoking cessation in heavy-drinking smokers is
combining effective smoking cessation pharmacotherapies
with pharmacotherapies that impact alcohol use (Yardley
et al., 2015). In this study, we focused on naltrexone, an opi-
ate antagonist that is Food and Drug Administration (FDA)-
approved for alcohol use disorder treatment and has been
shown to reduce heavy drinking in non-abstinence-oriented
alcohol treatments (Kranzler et al., 2003; Morgenstern et al.,
2012; O’Malley et al., 2015). Although some laboratory stud-
ies (Epstein and King, 2004; King and Meyer, 2000; Rohse-
now et al., 2007; Rukstalis et al., 2005) but not others
(Epstein and King, 2004; Rohsenow et al., 2007; Sutherland
et al., 1995) have suggested that naltrexone may reduce crav-
ing and the reinforcing value of cigarettes, its efficacy as a
smoking cessation pharmacotherapy has not been supported
(Hartmann-Boyce et al., 2014). One recent exception demon-
strated short-term efficacy for smoking cessation when nal-
trexone was combined with bupropion (Mooney et al., 2016).
There is some evidence from a human laboratory study
that naltrexone may reduce the effect of alcohol use on cigar-
ette craving in nontreatment seeking heavy-drinking light
smokers (Ray et al., 2007), which suggests that naltrexone
could protect against lapses to smoking that occur when
recently quit smokers are drinking. This hypothesis has not
been evaluated in a treatment-oriented clinical trial. How-
ever, 2 randomized clinical trials that evaluated naltrexone
versus placebo combined with nicotine patch for smoking
cessation have conducted post hoc analyses to determine
whether naltrexone had beneficial effects on alcohol use and
smoking outcomes in participants who were heavy drinkers.
One study found that 12 weeks of naltrexone 50 mg/d com-
pared to placebo increased smoking abstinence and reduced
alcohol use during treatment in heavy-drinking participants
but not in moderate-to-light drinkers or nondrinkers (Frid-
berg et al., 2014). A second study compared 6 weeks of 25,
50, and 100 mg of naltrexone daily to placebo, and found
that both 25 and 50 mg naltrexone decreased alcohol use rel-
ative to placebo; however, there was no benefit for smoking
cessation (O’Malley et al., 2009). Thus, there is (i) evidence
that naltrexone may reduce heavy drinking in the context of
smoking cessation and (ii) mixed evidence that naltrexone
may promote smoking cessation in the subset of smokers
who drink heavily. No published studies to date have been
designed a priori to test the effects of naltrexone among
heavy-drinking smokers, nor have any studies tested naltrex-
one in the context of counseling that addresses both smoking
cessation and heavy drinking. Therefore, the utility of nal-
trexone for heavy drinkers seeking smoking cessation treat-
ment remains unclear.
Study Aims
The purpose of this study was to test the efficacy of a 10-
week course of 50 mg/d of naltrexone on alcohol use and
smoking outcomes among heavy drinkers seeking smoking
cessation treatment. As in the Fridberg and colleagues (2014)
and O’Malley and colleagues (2009) studies, participants
received transdermal nicotine patch starting on their target
quit smoking date. Unlike those studies, we did not exclude
participants whomet criteria for DSM-IV alcohol dependence
(American Psychiatric Association, 1994), and all participants
received counseling that addressed both alcohol and smoking.
We hypothesized that naltrexone, compared to placebo,
would result in greater reductions in frequency of heavy drink-
ing days during treatment and in the 4 months after treat-
ment. We further hypothesized that naltrexone would (i)
reduce the odds of having an alcohol-involved smoking lapse
during treatment, and (ii) increase the odds of smoking absti-
nence at 2, 8, 16, and 26 weeks after participants’ target quit
smoking date. Smoking abstinence was considered a sec-
ondary outcome given the mixed evidence of the efficacy of
naltrexone for that outcome. In addition, we tested the
hypothesis that naltrexone’s effects would be moderated by
alcohol dependence, such that its efficacy for reducing drink-
ing and enhancing smoking cessation would be most evident
in those with current alcohol dependence. We also tested
whether gender moderated naltrexone’s effects given mixed
evidence regarding whether women or men benefit differently
from naltrexone for alcohol dependence (Garbutt et al., 2014)
and smoking cessation (Epperson et al., 2010; King et al.,
2012).
MATERIALS ANDMETHODS
Study Design
We utilized a randomized double-blind, placebo-controlled trial
to test the efficacy of 10 weeks of naltrexone 50 mg/d for decreasing
heavy drinking and increasing smoking abstinence among heavy
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drinkers seeking smoking cessation treatment. All participants
received 6 weeks of treatment with transdermal nicotine patch and
6 sessions of counseling that focused on smoking cessation, alcohol
reduction, and utilization of study medication. Outcomes were
assessed through 26 weeks after participants’ target quit smoking
dates. The study was approved by the Brown University and Lifes-
pan Hospitals Institutional Review Boards (ClinicalTrials.gov:
NCT00938886).
Sample Size and Power. We set desired sample size to detect a
small to medium effect of naltrexone (d = 0.30) on percent heavy
drinking days with power of 0.80 and a = 0.05, assuming 3 follow-
up assessments and correlations among those repeated measures
that mirrored our prior study (Kahler et al., 2008). Required sample
size was estimated at 134 participants per condition. Allowing for
attrition from follow-up of about 10%, we sought to recruit a total
sample of 300. However, due to persistent difficulties in recruiting
participants, we were only able to randomize 150 total participants,
of whom 133 completed 26-week follow-up; the reduced sample size
meant that we had power of 0.80 to detect an effect size d of 0.43,
but only power of 0.50 to detect a d of 0.30.
Participants
Participants were recruited from Providence, RI, and the sur-
rounding community through bulletin board, radio, Internet,
newspaper, and public transportation advertisements. Addition-
ally, we posted flyers in physicians’ offices and recruited directly
from university-affiliated primary care clinics. To be included,
participants had to (i) be ≥ 18 years old; (ii) have smoked cigar-
ettes regularly for at least 1 year; (iii) currently smoke ≥ 5 cigar-
ettes a day; (iv) currently use no other tobacco products or
nicotine replacement therapy; and (v) currently report drinking
heavily at least once per month on average (≥ 4 drinks per occa-
sion for women; ≥ 5 drinks for men). Participants were excluded
if they (i) met DSM-IV criteria for substance dependence (exclud-
ing nicotine and alcohol) in the past 12 months; (ii) reported opi-
oid use in the past month, had a drug screen positive for
opioids, or required opioid medication for pain management; (iii)
met criteria for a current major depressive or manic episode; (iv)
had current psychotic symptoms; (v) had an unstable or serious
medical condition that would preclude use of nicotine patch or
naltrexone; (vi) had aspartate aminotransferase or alanine amino-
transferase levels more than 3 times the reference range, or clini-
cally elevated bilirubin levels; or (vii) were currently pregnant or
lactating, intended to become pregnant, or were not using a reli-
able method of birth control. We excluded participants with a
history of severe alcohol withdrawal and those currently receiving
treatment for a primary alcohol problem.
Study Procedure
Potential participants were screened by telephone before com-
pleting an intake interview, at which they signed informed consent.
Participants were recruited from October 2009 through April 2015,
and follow-ups were conducted from January 2010 through October
2015. Figure 1 provides the CONSORT diagram of participant flow.
Baseline Assessment and Physical Examination
The baseline interview assessed demographic information; alco-
hol, tobacco, and other drug use; and vital signs. A breath alcohol
level was taken, and those with a detectable breath alcohol concen-
tration (BrAC) were rescheduled. Participants provided blood and
urine specimens for pregnancy and laboratory testing. The study
medical provider made final eligibility determination based on these
results and physical examination findings.
Randomization
Eligible participants were assigned to medication condition by a
staff member uninvolved in assessment using computerized urn ran-
domization (Wei, 1978), to ensure balance on gender, score on the
Fagerstr€om Test for Nicotine Dependence (FTND; Heatherton
et al., 1991), drinks consumed per week, and intention to change
drinking while quitting smoking. Seventy-five participants were ran-
domized to placebo and 75 to naltrexone. The study medical provi-
der dispensed blinded study medications at the conclusion of the
physical examination.
Counseling andMedication Management
Counseling and medication management (CMM) comprised 6
individual counseling sessions over a 9-week period with quit date
occurring at session 2. Following physical examination, eligible par-
ticipants were scheduled for a counseling session during the follow-
ing week. Counseling was delivered by 6 female counselors with
prior experience in nursing or counseling (3 were bachelor’s-level
nurses, 1 held a master’s degree, and 2 held doctoral degrees). Coun-
selors used detailed manuals to ensure standardization of treatment
delivery. They completed approximately 20 hours of training in
motivational interviewing (Miller and Rollnick, 2012) and smoking
cessation counseling, including assigned readings and group didactic
sessions. They discussed each case at a weekly group supervision
meeting led by a licensed clinical psychologist (CWK). All sessions
were audio-recorded for supervision purposes.
The CMM intervention provided (i) smoking cessation treatment
consistent with clinical practice guidelines (Brown et al., 2014; Fiore
et al., 2008; Kahler et al., 2008), (ii) counseling on alcohol and its
impact on smoking cessation (Kahler et al., 2008), and (iii) monitor-
ing of oral study medication use and safety following guidelines in
medical management (Pettinati et al., 2004). Session 1 occurred
1 week after physical examination and initiation of study medica-
tion. It focused on preparation for quitting smoking, identifying
high-risk situations, enlisting social support, and developing coping
strategies. Normative feedback was provided on drinking and risk
of smoking relapse associated with drinking. The role of alcohol use
in smoking relapse served as an entry into discussion of possible
short- and long-term changes in drinking. This session included
monitoring of naltrexone adherence, as well as provision of nicotine
patch and instruction in its use. Session 2 occurred the following
week and coincided with participants’ target quit smoking date,
with sessions 3 to 6 occurring 1, 2, 4, and 8 weeks after quit date,
respectively. These sessions focused on study medication use, side
effects, progress in quitting smoking, provision of support, review of
current drinking, efforts to modify drinking, and problem solving
for high-risk situations for smoking relapse. Session 1 lasted
approximately 40 minutes with remaining sessions lasting 20 min-
utes. A BrAC was taken on participants before each session, and
sessions were rescheduled if BrAC was over 0.02, which occurred at
less than 1% of sessions.
Pharmacotherapy
Participants were instructed to take their first dose of study oral
medication at the conclusion of the physical examination (2 weeks
before the target quit smoking date) and to take 1 tablet daily for
10 weeks. The first titration doses of 12.5 and 25 mg were packed
by the pharmacist in individual glassine envelopes and placed within
the medication bottle. Those assigned to placebo received pills that
were indistinguishable from active medication. Medication bottles
were fitted with child-resistant MEMS6 TrackCaps from AAR-
DEX Ltd. (Sion, Switzerland), which electronically recorded dates
and times of bottle openings. All participants were told there was a
50 to 50 chance of receiving naltrexone or placebo and that neither
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they nor their treatment providers would be informed which medi-
cation they received. Participants were instructed to bring their med-
ication bottle to each visit for pill counts and downloading of
TrackCap data.
All participants received a 6-week course of transdermal nicotine
patch: 21 mg for 2 weeks (14 mg for those smoking 5 to 10 cigar-
ettes per day) followed by 14 mg for 2 weeks and then 7 mg for
2 weeks. Participants were instructed to apply the patch imm-
ediately upon waking on their quit date and to apply 1 patch
daily thereafter. Participants were informed of the efficacy of nico-
tine patch for smoking cessation, and adherence was strongly
encouraged.
Assessments
Participants completed assessments at baseline and each counsel-
ing session. In addition, follow-ups were conducted at 8, 16, and
26 weeks after participants’ quit date. Research assistants who
Screened by phone for eligibility 
(N = 1697) -Declined to participate prior to 
screener (n = 38)
-Did not meet eligibility criteria (n = 
1055)
Met initial eligibility criteria 
(N = 604)
Completed baseline assessment 
(N = 267)
Randomized (N = 150)
-Not shown for baseline (n = 207)
-Declined to participate prior to 
baseline (n = 91)
-Recruited into alternate study (n = 
39)
-Did not meet eligibility criteria 
(n = 95)
-Dropped out after consent (n = 14)
-Failed physical examination (n = 8)
Naltrexone (n = 75)Placebo (n = 75)
Analyzed (n = 75)
• Did not attend any sessions (n = 5)
• Attended 1-5 sessions (n = 34)
• Attended all 6 sessions (n = 36)
Analyzed (n = 75)
• Did not attend any sessions (n = 5)
• Attended 1-5 sessions (n = 30)
• Attended all 6 sessions (n = 40)
Status at Follow-up
• Completed assessment (n = 60)
• Missed/could not locate (n = 8)
• Withdrawn (n = 6)
• Deceased (n = 1)
Status at Follow-up
• Completed assessment (n = 58)
• Missed/could not locate (n = 10)
• Withdrawn (n = 6)
• Deceased (n = 1)
Status at Follow-up
• Completed assessment (n = 65)
• Missed/could not locate (n = 2)
• Withdrawn (n = 7)
• Deceased (n = 1)
Status at Follow-up
• Completed assessment (n = 68)
• Missed/could not locate (n = 3)
• Withdrawn (n = 4)
Status at Follow-up
• Completed assessment (n = 67)
• Missed/could not locate (n = 4)
• Withdrawn (n = 4)
Status at Follow-up
• Completed assessment (n = 67)
• Missed/could not locate (n = 4)
• Withdrawn (n = 4)
Week 8 
Follow-up
Week 16 
Follow-up
Week 26 
Follow-up
Fig. 1. CONSORT diagram showing participant flow.
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conducted interviews were not informed of medication assignment.
Multiple methods were used to maximize retention in follow-ups
including payments ($30, $30, and $50, at 8, 16, and 26 weeks,
respectively), phone and letter reminders about follow-up appoint-
ments, and use of collateral informants to gather contact informa-
tion on participants lost to follow-up.
Structured Clinical Interview for DSM-IV. Diagnostic exclu-
sions and lifetime prevalence of key Axis I diagnoses were deter-
mined at baseline by the substance use and affective disorders
sections of the Structured Clinical Interview for DSM-IV (SCID),
nonpatient version (First et al., 1995). The SCID was administered
by trained interviewers and supervised by licensed psychologists
who regularly reviewed audiotaped interviews.
Medical Screening and Vital Signs. At baseline, participants
completed a medical screen focused on contraindications for using
nicotine patch and naltrexone. Vital signs were also taken at base-
line and each assessment. Participants completed a urine drug screen
and provided a blood sample for liver function testing. At baseline,
the Clinical Institute Withdrawal Assessment for Alcohol—Revised
(CIWA-Ar; Sullivan et al., 1989) was administered to determine
whether overnight abstinence from alcohol led to clinically signifi-
cant alcohol withdrawal symptoms.
Alcohol Use and Withdrawal. The Timeline Follow-Back Inter-
view (TLFB; Sobell and Sobell, 1996), a well-validated calendar-
assisted interview, was used at baseline to assess alcohol use in the
prior 8 weeks. TLFB was conducted at each counseling session, and
at 8-, 16-, and 26-week follow-ups to assess alcohol use since last
study visit. From the TLFB, we calculated 2 outcome variables: per-
cent heavy drinking days (primary alcohol use outcome) and aver-
age drinks per week (secondary alcohol use outcome). Alcohol
withdrawal symptoms were assessed by the Short Alcohol With-
drawal Scale (Gossop et al., 2002) and the CIWA-Ar at all treat-
ment sessions; no participants required medical detoxification.
Cigarette Smoking and Nicotine Dependence. The FTND pro-
vided a continuous measure of nicotine dependence, and the TLFB
assessed number of cigarettes smoked per day (Brown et al., 1998).
Smoking data were collected with the TLFB at each counseling ses-
sion and at all follow-ups. A relapse interview (Kahler et al., 2010)
was administered to participants who lapsed to smoking after quit
date to determine the circumstances surrounding the initial lapse
episode, including whether individuals were drinking alcohol.
Our primary smoking outcome was biochemically verified 7-day
point-prevalence smoking abstinence at 2, 8, 16, and 26 weeks after
quit date. Self-reported abstinence was verified at all assessments
using carbon monoxide (CO) analysis of breath samples with a
4 ppm cutoff (Cropsey et al., 2014), and at 8, 16, and 26 weeks, it
was also verified using saliva cotinine (cutoff value of 15 ng/ml)
(SRNT Subcommittee on Biochemical Verification, 2002) as deter-
mined by enzyme immunoassay. Abstinence was verified by having
both CO and cotinine levels under the stated cutoffs. For those who
reported using nicotine replacement at the 8-, 16-, and 26-week fol-
low-ups, we relied only on CO for biochemical verification. For
those who were unable to come to the study center, we confirmed
smoking abstinence by calling a collateral informant whose contact
information was provided by the participant at baseline. Only indi-
viduals who had smoking abstinence confirmed at a given follow-up
were considered abstinent; those with missing data were considered
nonabstinent. We also ran analyses in which no assumptions
were made about missing data; results using no missingness assump-
tions were highly concordant with those using a “worst-case”
assumption and are therefore not detailed here. Our secondary
smoking outcome was continuous smoking abstinence, defined as
reporting no smoking from 2 to 26 weeks after quit date (Hughes
et al., 2003) and being verified abstinent at each follow-up. We also
categorized participants as continuously abstinent or not during
active treatment.
Medication Side Effects and Adherence. At each treatment ses-
sion, a side effects checklist was completed based on the Systematic
Assessment For Treatment Emergent Events (SAFTEE) (Levine
and Schooler, 1986; Pettinati et al., 2004), which was modified to
assess the most common side effects of naltrexone and nicotine
patch. Participants were asked whether they experienced each symp-
tom since their previous study visit, and the counselor rated the
symptom as minimal, mild, moderate, or severe based on protocol
guidelines.
Adherence to oral study medication was assessed by self-report,
pill count, and MEMS6 TrackCaps. Pills taken and nicotine
patch use were recorded for each day using the TLFB. TrackCaps
data were downloaded and pill counts conducted at each treatm-
ent session.
Data Analysis Plan
We examined demographic and clinical characteristics in the
sample as a whole and within each treatment condition. We next
examined session attendance, nicotine patch use, oral medication
adherence, and occurrence of adverse events. We used t-tests and
chi-square tests to determine whether there were significant
between-condition differences on these variables.
Alcohol Outcomes. We examined primary (percent heavy
drinking days) and secondary (average drinks per week) alcohol
use outcomes during weeks 3 to 10 on medication (corresponding
to weeks 1 to 8 after target quit smoking date), during weeks 9 to
16 after quit date (when no longer on medication), and during
weeks 17 to 26 after quit date; these variables were log-trans-
formed to correct positive skewness and standardized so that
model coefficients could be interpreted as effect size d. To examine
the effect of treatment (dummy coded with placebo as the refer-
ence group) within the context of other covariates, repeated-mea-
sures analyses were conducted using generalized estimating
equations (GEE) (Zeger and Liang, 1986) using PROC GEN-
MOD in SAS (SAS Institute Inc., 2012); GEE is particularly
robust to model misspecification and well-suited for addressing
marginal (i.e., between groups) effects. Analyses controlled for fac-
tors in the urn randomization (gender, FTND, drinks per week,
and the linear effect of intention to change drinking). A linear
effect of time (centered) and a time by group interaction were
included to test whether naltrexone effects became weaker once
treatment was completed. In a second step, we added alcohol
dependence and the naltrexone by alcohol dependence interaction
to test whether naltrexone effects were stronger among those with
current alcohol dependence and also added the interaction
between naltrexone and gender. Analyses included all 136 partici-
pants (90.7% of the sample) who provided any follow-up data on
alcohol use. The proportion of participants providing alcohol fol-
low-up data did not differ by medication condition (88.0% in pla-
cebo vs. 93.3% in naltrexone, v2 = 1.26, p = 0.26). As a
supplemental approach to examine the effect of naltrexone under
relatively high rates of medication adherence, analyses for alcohol
and smoking outcomes were repeated including only participants
who took at least two-thirds of medication doses across all adher-
ence measures (n = 72). For both alcohol and smoking outcomes,
we examined whether including counselor as a term in GEE mod-
els improved model fit or altered conclusions and found it did not.
Smoking Outcomes. We ran logistic regression analyses with the
a priori covariates to predict the odds of having an alcohol-involved
lapse to smoking during treatment. We then used GEE with a
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binomial distribution and logit link function to analyze the odds of
smoking abstinence at 2, 8, 16, and 26 weeks after quit date. A lin-
ear effect of time (centered) and a time by group interaction were
also included. We then added naltrexone by alcohol dependence
and naltrexone by gender interactions to the model. We used logistic
regression to test whether naltrexone was associated with greater
odds of continuous smoking abstinence during active treatment and
over the course of the study.
RESULTS
Baseline Characteristics
Sample characteristics are shown in Table 1. For all vari-
ables examined, conditions did not differ significantly.
Treatment Exposure and Adverse Events
Table 2 shows session attendance, nicotine patch use, and
medication adherence. Percent of medication doses taken did
not differ significantly by condition whether estimated by
self-report, pill count, or bottle openings. For both nicotine
patch and oral medication, participants self-reported using
about three-quarters of the medications they were given.
Oral medication adherence estimated by vial openings was
substantially lower than both self-report and pill count esti-
mates.
Adverse effects to study medications of any degree (mini-
mal, mild, moderate, severe) were reported by 126 (84.0%)
of participants, and the most common were insomnia, fati-
gue, and anxiety/nervousness. There were no differences on
the overall frequency of adverse effects of any degree by med-
ication condition (v2 (1) = 0.257, p = 0.61). The most com-
mon moderate–severe adverse effects reported were insomnia
(21.4%), somnolence (17.9%), anxiety (13.6%), depression
(11.4%), vomiting (10.0%), and headache (10.0%); the per-
centage of participants reporting moderate–severe adverse
effects did not differ significantly by condition (all ps > 0.05).
Only 1 study participant reported intolerable adverse effects
and was advised to cease taking medication.
Drinking Outcomes
Table 2 shows percent heavy drinking days and average
number of drinks per week at each follow-up. Compared to
baseline, participants in both conditions showed large and
significant reductions in alcohol use at each follow-up
(ps < 0.0001 using paired t-tests). However, the differences
between conditions at all time points were minimal. The
unadjusted effects sizes for condition differences at each fol-
low-up are shown in Table 2.
GEE analysis of percent heavy drinking days including a
priori covariates indicated that the effect of naltrexone versus
Table 1. Baseline Demographic and Clinical Characteristics for the Entire Sample and by Treatment Condition (N = 150)
Overall (N = 150) Placebo (n = 75) Naltrexone (n = 75)
n (%) orM (SD) n (%) orM (SD) n (%) orM (SD)
Female gender 62 (41.3%) 29 (38.7%) 33 (44.0%)
Years of age 42.1 (12.7) 41.8 (12.9) 42.3 (12.7)
Racea
White 109 (74.2%) 54 (74.0%) 55 (74.3%)
Black/African American 25 (17.0%) 12 (16.4%) 13 (17.6%)
Native American 3 (2.0%) 3 (4.1%) 0 (0.0%)
Asian 5 (3.4%) 3 (4.1%) 2 (2.7%)
Multiple races 5 (3.4%) 1 (1.4%) 4 (5.4%)
Hispanic/Latinob 9 (6.0%) 7 (9.4%) 2 (2.7%)
Education
< High school 13 (8.7%) 5 (6.7%) 8 (10.7%)
High school 40 (26.7%) 18 (24.0%) 22 (29.3%)
Some college 60 (40.0%) 35 (46.7%) 25 (33.3%)
College graduate 37 (24.7%) 17 (22.7%) 20 (26.7%)
Unemployed 57 (38.0%) 31 (41.3%) 26 (34.5%)
Married or cohabiting 28 (18.7%) 15 (20.0%) 13 (17.3%)
Clinical characteristics
Current alcohol dependence 42 (28.0%) 19 (25.3%) 23 (30.7%)
Percent heavy drinking days 34.0 (26.2) 33.9 (24.9) 34.2 (27.7)
Drinks per week 25.2 (23.7) 26.5 (26.5) 23.9 (20.6)
Intent to change drinkingc
No 7 (4.7%) 3 (4.0%) 4 (5.3%)
Possibly 35 (23.3%) 16 (21.3%) 19 (25.3%)
Probably 57 (38.0%) 30 (40.0%) 27 (36.0%)
Definitely 51 (34.0%) 26 (34.7%) 25 (33.3%)
Cigarettes smoked per day 17.4 (8.8) 17.9 (10.2) 16.9 (7.2)
FTND score 5.3 (2.3) 5.4 (2.3) 5.3 (2.2)
FTND, Fagerstr€om Test for Nicotine Dependence.
aThree participants did not answer this question.
bOne participant did not answer this question.
cParticipants were asked whether they planned to cut down or stop drinking while quitting smoking.
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placebo was minimal and nonsignificant (B = 0.04, 95%
CI [0.30, 0.22], p = 0.76). The naltrexone by time interac-
tion also was nonsignificant (B = 0.01, 95% CI [0.14,
0.12], p = 0.84), indicating that the effect of naltrexone did
not differ significantly over time. Higher baseline number of
drinks per week was associated with significantly higher per-
cent heavy drinking days (B = 0.30, 95% CI [0.14, 0.45],
p = 0.0002), and greater baseline intention to reduce drink-
ing during smoking cessation was associated with signifi-
cantly lower percent heavy drinking days (B = 0.35, 95%
CI [0.50, 0.21], p < 0.0001). In the second step of the
model, neither the naltrexone by alcohol dependence
(B = 0.06, 95% CI [0.60, 0.48], p = 0.83) nor the naltrex-
one by female gender (B = 0.27, 95% CI [0.30, 0.84],
p = 0.35) interactions were significant.
The main effect of naltrexone on number of drinks per
week was nonsignificant (B = 0.09, 95% CI [0.35, 0.18],
p = 0.54), as was the naltrexone by time interaction
(B = 0.08, 95% CI [0.20, 0.05], p = 0.23). Interactions
between naltrexone and both alcohol dependence and gender
were nonsignificant, ps > 0.60. Effect sizes for naltrexone for
percent heavy drinking days and drinks per week remained
similar when analyses were restricted to those with high med-
ication adherence: B = 0.09, 95% CI [0.41, 0.24] and
B = 0.13, 95% CI [0.48, 0.22], respectively.
Exploratory analyses of drinking outcomes in the 2 weeks
prior to target quit smoking date, as well as analyses of
drinks per drinking day as an outcome variable, did not indi-
cate any advantage of naltrexone over placebo. Finally, we
ran a model including abstinence from smoking at the time
of alcohol assessment to determine whether smoking out-
comes were associated with drinking outcomes. The time-
varying effect of smoking abstinence on percent heavy drink-
ing days (B = 0.06, 95% CI [0.26, 0.15], p = 0.58) and
drinks per week (B = 0.03, 95% CI [0.22, 0.16], p = 0.77)
was nonsignificant.
Smoking Outcomes
Overall, 131 participants provided daily data on smoking
during treatment (weeks 1 to 8 after quit date), of whom 99
reported a smoking lapse. Of these lapses, 34 (34.3%)
occurred when participants were drinking (see Table 2).
Multiple logistic regression analyses indicated that although
Table 2. Alcohol Use and Smoking Outcomes by Treatment Condition
Placebo (n = 75) Naltrexone (n = 75) Effect size
M (SD) M (SD) d
Treatment exposure
Counseling sessions completed 3.8 (1.6) 3.9 (1.6) 0.08
%Days using patch: self-report 74.6 (31.1) 78.4 (31.2) 0.12
%Medication doses taken
Self-report 76.8 (28.5) 76.3 (31.3) 0.02
Pill count 69.6 (27.6) 74.7 (30.5) 0.18
Vial openings by MEMS Cap 55.4 (33.1) 61.1 (33.2) 0.17
Drinking outcomes
Percent heavy drinking days
(Baseline) (n = 150) 33.9 (24.9) 34.2 (27.7) N/A
Weeks 1 to 8 after quit date (n = 132) 12.4 (19.2)f 15.3 (24.6)f 0.04a
Weeks 9 to 16 after quit date (n = 132) 18.7 (26.1)f 18.7 (26.6)f 0.02a
Week 17 to 26 after quit date (n = 131) 16.0 (20.8)f 17.0 (24.5)f 0.01a
Drinks per week
(Baseline) (n = 150) 26.5 (26.5) 23.9 (20.6) N/A
Weeks 1 to 8 after quit date (n = 132) 9.9 (10.4)f 10.7 (12.0)f 0.02a
Weeks 9 to 16 after quit date (n = 132) 11.9 (12.3)f 11.8 (12.4)f 0.05a
Week 17 to 26 after quit date (n = 131) 11.4 (11.3)f 11.1 (13.1)f 0.14a
Smoking outcomes % % h
Alcohol-involved smoking lapseb 31.8 20.6 0.26
7-day point-prevalence abstinencec
2 weeks after quit date 28.0 37.3 0.20
8 weeks after quit date 22.7 20.0 0.07
16 weeks after quit date 18.7 16.0 0.07
26 weeks after quit date 12.0 12.0 0.00
Abstinence during treatmentc,d 14.7 16.0 0.04
Continuous smoking abstinencec,e 8.0 5.3 0.11
aEffect size calculated from log-transformed values due to positive skewness.
bStatistic based on 131 participants who provided complete data regarding whether they lapsed to smoking when drinking alcohol in the 8 weeks after
smoking quit date.
cIncludes all 150 participants, assuming that only those biochemically confirmed as abstinent were not smoking.
dDefined as no smoking from 2 weeks after quit date through the 8-week follow-up.
eDefined as no smoking from 2 weeks after quit date through the 26-week follow-up.
fIndicates significant reduction versus baseline according to paired t-tests, all ps < 0.0001.
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the effect of naltrexone on reducing the odds of having an
alcohol-involved lapse to smoking was in the hypothesized
direction, it was nonsignificant, odds ratio (OR) = 0.51,
95% CI [0.22, 1.14], p = 0.10.
The percent of all participants in each condition who were
biochemically confirmed abstinent from smoking at 2, 8, 16,
and 26 weeks is shown in Table 2. GEE analyses including a
priori covariates indicated that the effect of naltrexone versus
placebo on smoking abstinence was minimal, contrary to the
hypothesized direction of effect, and nonsignificant,
OR = 0.93, 95% CI [0.46, 1.86], p = 0.83. The naltrexone by
time interaction also was nonsignificant (OR = 0.82, 95% CI
[0.61, 1.11], p = 0.20). No baseline covariates were signifi-
cantly associated with smoking abstinence. Neither the nal-
trexone by alcohol dependence (OR = 1.17, 95% CI [0.27,
5.06], p = 0.83) nor the naltrexone by female gender
(OR = 0.55, 95% CI [0.15, 1.99], p = 0.36) interactions were
significant. Analyses restricted to those with high medication
adherence also yielded an effect for naltrexone in the oppo-
site direction hypothesized: OR = 0.61, 95% CI [0.26, 1.42].
Logistic regression analysis of the odds of continuous smok-
ing abstinence during active treatment (OR = 1.09, 95% CI
[0.44, 2.71], p = 0.85) and across 26 weeks (OR = 0.62, 95%
CI [0.15, 2.29], p = 0.48) indicated that the effect of naltrex-
one was nonsignificant.
DISCUSSION
Our study provided no evidence that naltrexone compared
to placebo reduced alcohol use or enhanced smoking cessa-
tion outcomes in heavy drinkers seeking smoking cessation
treatment. It is important to note that we were not able to
achieve our desired sample size, thereby resulting in less-
than-desired statistical power. However, the effect sizes
observed for naltrexone were well below the effect size on
which we powered the trial, suggesting that any effects of nal-
trexone likely would have been minimal. These results are
inconsistent with 2 post hoc analyses of smaller subsamples
of heavy drinkers in smoking cessation trials, which found
naltrexone reduced alcohol use (O’Malley et al., 2009;
n = 102; Fridberg et al., 2014; n = 69) and enhanced smok-
ing cessation (Fridberg et al., 2014).
The negative findings of this trial, compared to the afore-
mentioned trials, may have resulted from a few key design
features. First, our study included counseling that explicitly
addressed alcohol use within smoking cessation counseling; a
version of this counseling has been shown to reduce drinking
by about 40% (Kahler et al., 2008). In contrast, studies by
Fridberg and colleagues (2014) and O’Malley and colleagues
(2009) did not focus on drinking. Second, as part of counsel-
ing, all participants were informed that naltrexone might
help them reduce drinking and thereby facilitate smoking
cessation. Placebo effects in alcohol trials are robust and
associated with reduced treatment effect size (Litten et al.,
2013). In the present study, percent heavy drinking days and
average drinks per week reduced by about 50% in the
placebo condition; in Fridberg and colleagues (2014), drink-
ing was relatively unchanged in those receiving placebo, and
in O’Malley and colleagues (2009), 85% of those receiving
placebo continued to drink heavily. Thus, a combination of
factors in the current study may have led to reductions in
drinking across all participants that were sufficiently large to
obscure naltrexone effects. Finally, studies that have estab-
lished the efficacy of naltrexone for reducing alcohol con-
sumption (Jonas et al., 2014) have typically been conducted
in very heavy drinking individuals, who may have more
room for showing improvements in drinking compared to
those in the present study. However, participants in this
study drank substantially more heavily at baseline compared
to the Fridberg and colleagues (2014) and O’Malley and col-
leagues (2009) heavy-drinking subsamples; therefore, it is
unclear whether the level of drinking in this sample accounts
for the negative findings.
An alternative hypothesis for the negative results of the
present trial is that naltrexone concentrations achieved may
not have been sufficient to lead to adequate blockade of
brain mu opioid receptors, presumed to be a primary mecha-
nism of action for naltrexone. Adherence to naltrexone was
modest (55 to 78% of possible doses taken), and we did not
have biochemical assessment of naltrexone metabolites. In
the Fridberg and colleagues (2014) and O’Malley and collea-
gues (2009) trials, adherence was estimated at 75 to 78%.
Given that higher naltrexone adherence is associated with
better outcomes (Swift et al., 2011), we cannot exclude the
possibility that a naltrexone effect would have been detected
had medication adherence been higher. However, we found
no evidence of higher effect sizes for naltrexone among those
with relatively high oral medication adherence. Finally,
although results of the O’Malley and colleagues (2009) dose-
ranging study tended to support a 25 or 50 mg naltrexone
dose, it is possible that a 100 mg dose may have had a stron-
ger effect in the present sample given higher levels of drinking
and alcohol dependence.
Smoking cessation rates in the present study were low.
These low rates may reflect the nature of the sample
recruited, which was characterized by low education, high
rates of unemployment, and heavy drinking, known risk fac-
tors for poor smoking cessation outcomes. They also could
reflect the short duration of nicotine replacement therapy
used (i.e., 6 weeks vs. 10+ weeks), although an association
between longer nicotine replacement therapy and better
smoking outcome has not been demonstrated (Stead et al.,
2012). Although more intensive counseling may have
increased smoking cessation rates, there is not clear evidence
that increasing intensity of behavioral interventions com-
bined with pharmacotherapy increases quit rates (Stead
et al., 2016). Given that the primary benefit of naltrexone on
smoking cessation was expected to be due to its effects on
drinking, the lack of an effect of naltrexone on smoking ces-
sation was not surprising and adds further to the literature
indicating that naltrexone is not an efficacious smoking ces-
sation pharmacotherapy (Hartmann-Boyce et al., 2014). The
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only indication of potential benefit of naltrexone, which was
not statistically significant, was in the 2 weeks immediately
after the target quit smoking date. Kappa opioid receptors
(KORs) have been implicated in nicotine withdrawal (Jack-
son et al., 2015), and it is possible that naltrexone has some
limited benefit to smoking cessation in the early phases of
smoking cessation by antagonizing KORs.
We examined 2 potential moderators of naltrexone’s effi-
cacy, alcohol dependence, and gender. Current alcohol
dependence was not significantly associated with drinking or
smoking outcomes and did not interact significantly with nal-
trexone. Thus, in the context of smoking cessation counsel-
ing that includes a substantial focus on reducing drinking,
smokers with alcohol dependence appear capable of making
meaningful reductions in drinking and achieving similar
smoking outcomes to heavy drinkers without alcohol depen-
dence. Gender also did not significantly moderate naltrexone
effects on drinking or smoking outcomes; future studies
examining gender differences, however, should collect data
on menstrual cycle which may influence naltrexone response
(Roche and King, 2015). Future studies could examine other
potential moderators of naltrexone response such as family
history of alcohol dependence and polymorphisms in opioid
receptor genes (Garbutt et al., 2014).
Strengths and Limitations
This study featured rigorous experimental control, a broad
community recruitment strategy, and inclusion of smokers
with and without alcohol dependence. However, it had mod-
est statistical power due to under-enrollment of participants.
Low enrollment may have resulted from numerous factors:
(i) even with targeted recruitment, less than one-third of
potential participants met study inclusion criteria and only
half of those continued through baseline enrollment; (ii) the
smoking rate in Rhode Island—with a population of just
over 1 million—has fallen substantially; and (iii) effective
smoking cessation pharmacotherapy is widely available to
smokers, making study participation less attractive. Our
experience suggests the need for conducting smoking cessa-
tion research on high-risk subpopulations within larger pop-
ulation centers, in multisite trials, or within existing smoking
cessation programs.
The study did not have biochemical verification of naltrex-
one compliance or alcohol use. Only 1 dose of naltrexone
was tested. The relatively low threshold for heavy drinking in
study inclusion criteria and the fact that a substantial portion
of the sample had low interest in changing drinking may
have further reduced the potential impact of naltrexone.
CONCLUSIONS
This study had low power to detect the effect sizes for nal-
trexone typically seen in clinical trials, and participants were
only moderately adherent to study medication. Nonetheless,
with a sample of 150 participants, the effect sizes and
confidence intervals obtained provided no evidence that nal-
trexone provides benefit when given to heavy drinking smok-
ers who quit smoking while also receiving nicotine patch and
counseling to addresses both alcohol use and smoking cessa-
tion. Results do suggest, however, that heavy drinkers,
including those with current alcohol dependence, can make
substantial reductions in drinking when they try to quit
smoking and receive multiple sessions of counseling that
explicitly addresses heavy drinking. Furthermore, the present
results and those in previous trials using in-person counseling
(Kahler et al., 2008; O’Malley et al., 2009) indicate that
changes in drinking are relatively independent of smoking
cessation success. Thus, the context of smoking cessation
treatment offers an ideal opportunity in which to effect
changes in individuals who drink heavily; changes in drink-
ing may be sustained even in the likely case of failure to
maintain long-term smoking abstinence. However, the
potential value of alcohol pharmacotherapies in smoking
cessation treatment when used in combination with differing
levels of behavioral alcohol intervention requires further
study.
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